Credit Suisse analyst Vamil Divan upgraded Versartis two notches to Outperform from Underperform and raised its price target to $20 from $11. The analyst raised his sales estimates driven mainly by increased market share expectations for somavaratan both in the pediatric and adult indications He views risk/reward as attractive based on positive expectations for the Phase 3 VELOCITY study, setting the stage for regulatory approval of somavaratan in 2018 and expects relatively rapid conversion of the market from daily therapies to long-acting versions.